PTC Therapeutics, Inc. Proceeds from Stock Plans
PTC Therapeutics, Inc. (PTCT) reported Proceeds from Stock Plans of $3.16 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockPlans · last filed 2026-07-30
- PTC Therapeutics, Inc. proceeds from stock plans for the quarter ending 2025-12-31 was $3.12M, a 3.38% decline year-over-year.
- PTC Therapeutics, Inc. proceeds from stock plans for the quarter ending 2025-09-30 was $0.00.
- PTC Therapeutics, Inc. proceeds from stock plans for the quarter ending 2024-12-31 was $3.23M, a 50.12% increase year-over-year.
- PTC Therapeutics, Inc. proceeds from stock plans for the quarter ending 2024-09-30 was $0.00.
- PTC Therapeutics, Inc. proceeds from stock plans for fiscal 2025 was $5.94M, a 14.33% increase from fiscal 2024.
- PTC Therapeutics, Inc. proceeds from stock plans for fiscal 2024 was $5.20M, a 12.68% decline from fiscal 2023.
- PTC Therapeutics, Inc. proceeds from stock plans for fiscal 2023 was $5.95M, a 7.69% decline from fiscal 2022.
- PTC Therapeutics, Inc. proceeds from stock plans for fiscal 2022 was $6.45M, a 11.36% increase from fiscal 2021.
| Period end | Proceeds from Stock Plans 3 month | Proceeds from Stock Plans 6 month | Proceeds from Stock Plans 9 month | Proceeds from Stock Plans 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.16M 10-Q · filed 2026-07-30 | |||
| 2025-12-31 | $3.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $3.12M derived: sum of 2 quarters · filed 2026-02-19 | $5.94M 10-K · filed 2026-02-19 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $2.83M 10-Q · filed 2025-11-04 | ||
| 2025-06-30 | $2.83M 10-Q · filed 2026-07-30 | |||
| 2024-12-31 | $3.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $3.23M derived: sum of 2 quarters · filed 2026-02-19 | $5.20M 10-K · filed 2026-02-19 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.97M 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | $1.97M 10-Q · filed 2025-08-07 | |||
| 2023-12-31 | $2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $2.15M derived: sum of 2 quarters · filed 2026-02-19 | $5.95M 10-K · filed 2026-02-19 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $3.81M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $3.81M 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $3.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.34M derived: sum of 2 quarters · filed 2025-02-27 | $6.45M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $3.11M 10-Q · filed 2023-10-26 | ||
| 2022-06-30 | $3.11M 10-Q · filed 2023-08-03 | |||
| 2021-12-31 | $3.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $3.17M derived: sum of 2 quarters · filed 2024-02-29 | $5.79M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $2.63M 10-Q · filed 2022-10-27 | ||
| 2021-06-30 | $2.63M 10-Q · filed 2022-08-04 | |||
| 2020-12-31 | $2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $2.90M derived: sum of 2 quarters · filed 2023-02-21 | $5.30M 10-K · filed 2023-02-21 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $2.41M 10-Q · filed 2021-10-28 | ||
| 2020-06-30 | $2.41M 10-Q · filed 2021-07-29 | |||
| 2019-12-31 | $2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $2.01M derived: sum of 2 quarters · filed 2022-02-22 | $3.58M 10-K · filed 2022-02-22 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $1.56M 10-Q · filed 2020-10-29 | ||
| 2019-06-30 | $1.56M 10-Q · filed 2020-08-05 | |||
| 2018-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $1.49M derived: sum of 2 quarters · filed 2021-02-25 | $2.79M derived: sum of 3 quarters · filed 2021-02-25 | $2.79M 10-K · filed 2021-02-25 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $1.30M derived: sum of 2 quarters · filed 2019-10-30 | $1.30M 10-Q · filed 2019-10-30 | $2.40M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $1.30M 10-Q · filed 2019-08-06 | $2.40M derived: sum of 3 quarters · filed 2020-03-02 | $3.21M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-09 | $1.11M derived: sum of 2 quarters · filed 2020-03-02 | $1.91M derived: sum of 3 quarters · filed 2020-03-02 | $1.91M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $1.91M derived: sum of 2 quarters · filed 2020-03-02 | $1.91M derived: sum of 3 quarters · filed 2020-03-02 | $2.47M 10-K · filed 2020-03-02 |
| 2017-09-30 | $805.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $805.00K derived: sum of 2 quarters · filed 2018-11-05 | $1.36M 10-Q · filed 2018-11-05 | $1.36M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $557.00K 10-Q · filed 2018-08-07 | $557.00K derived: sum of 3 quarters · filed 2019-03-01 | $557.00K derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $557.00K 10-Q · filed 2018-05-09 | $557.00K derived: sum of 2 quarters · filed 2019-03-01 | $557.00K derived: sum of 3 quarters · filed 2019-03-01 | $557.00K derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $0.00 derived: sum of 2 quarters · filed 2019-03-01 | $0.00 derived: sum of 3 quarters · filed 2019-03-01 | $0.00 10-K · filed 2019-03-01 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $0.00 derived: sum of 2 quarters · filed 2017-11-02 | $0.00 10-Q · filed 2017-11-02 | |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $0.00 10-Q · filed 2017-08-09 | ||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-08 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |